Abstract
Purpose
No study has reported the risk of other site osteonecroses after the diagnosis of multifocal osteonecrosis related to corticosteroids in patients who continue this corticosteroid treatment. An analysis of the time-course to other sites of osteonecrosis, as well as the effects of underlying corticosteroid risk factor on the evolution of asymptomatic lesions at the time of diagnosis, is presented.
Methods
Two hundred patients were followed prospectively every year during a minimum ten years with a radiograph if a joint became symptomatic. In absence of evidence of osteonecrosis on radiographs of a symptomatic or non-symptomatic joint (hips, shoulders, knees, ankles), patients had an MRI performed at the most recent follow up. The average duration of follow-up after inclusion of the patient in the study was 15 years (range 10–20).
Results
Of the 200 patients followed for an average of 15 years (minimum 10 years, maximum 20 years), 35 patients developed new osteonecrosis lesions during the period of study. Asymptomatic lesions became symptomatic and a high number of collapse was observed resulting in 258 arthroplasties (187 hips, 51 shoulders, 20 knees) at the most recent follow up.
Conclusion
The continuation of peak doses (>200 mg) of corticosteroids predicted (p = 0.04) occurrence of new lesions and the continuation of corticosteroids without peak dose was a risk for quicker progression to collapse.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Collaborative Osteonecrosis Group (1999) Symptomatic multifocal osteonecrosis: a multicenter study. Clin Orthop 369:312–326
Hernigou P, Lambotte JC (2000) Bilateral hip osteonecrosis: influence of hip size on outcome. Ann Rheum Dis 59:817–821
Zhang NF, Li ZR, Wei HY, Liu ZH, Hernigou P (2008) Steroid-induced osteonecrosis; the number of lesions is related to the dosage. J Bone Joint Surg (Br) 90-B:1239–1243
Mont MA, Jones LC, Hungerford DS (2006) Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 88-A:1117–1132
LaPorte DM, Mont MA, Mohan V, Jones LC, Hungerford DS (1998) Multifocal osteonecrosis. J Rheumatol 25:1968–1974
Flouzat-Lachaniete CH, Roussignol X, Poignard A, Mukasa MM, Manicom O, Hernigou P (2009) Multifocal joint osteonecrosis in sickle cell disease. Open Orthop J 3:32–35
Drescher W, Schneider T, Becker C et al (2001) Selective reduction of bone blood flow by short-term treatment with high-dose methylprednisolone: an experimental study in pigs. J Bone Joint Surg (Br) 83-B:274–277
Drescher W, Weigert KP, Bünger MH et al (2004) Femoral head blood flow reduction and hypercoagulability under 24 h megadose steroid treatment in pigs. J Orthop Res 22:501–508
Kang JS, Moon KH, Kwon DG, Shin BK, Woo MS (2013) The natural history of asymptomatic osteonecrosis of the femoral head. Int Orthop 37:379–384
Yu T, Xie L, Zhang Z, Ke X, Liu Y (2015) Prediction of osteonecrosis collapse of the femoral head based on the proportion of the proximal sclerotic rim. Int Orthop 39:1045–1050
Mankin HJ (2007) Pathophysiology of osteonecrosis. Semin Arthroplast 18:170–174
Sugano N, Nishii T, Shibuya T, Nakata K, Masuhara K, Takaoka K (1997) Contralateral hip in patients with unilateral nontraumatic osteonecrosis of the femoral head. Clin Orthop 334:85–90
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Flouzat-Lachaniette, CH., Roubineau, F., Heyberger, C. et al. Multifocal osteonecrosis related to corticosteroid: ten years later, risk of progression and observation of subsequent new osteonecroses. International Orthopaedics (SICOT) 40, 669–672 (2016). https://doi.org/10.1007/s00264-015-3060-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00264-015-3060-8